OPKO Health (OPK) Competitors $1.45 -0.06 (-3.97%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$1.47 +0.02 (+1.66%) As of 09/19/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OPK vs. ALKS, LGND, FOLD, MNKD, CLDX, BCRX, NVAX, INVA, DVAX, and ZBIOShould you be buying OPKO Health stock or one of its competitors? The main competitors of OPKO Health include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), MannKind (MNKD), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Innoviva (INVA), Dynavax Technologies (DVAX), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry. OPKO Health vs. Its Competitors Alkermes Ligand Pharmaceuticals Amicus Therapeutics MannKind Celldex Therapeutics BioCryst Pharmaceuticals Novavax Innoviva Dynavax Technologies Zenas BioPharma OPKO Health (NASDAQ:OPK) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership. Which has preferable valuation & earnings, OPK or ALKS? Alkermes has higher revenue and earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOPKO Health$713.10M1.61-$53.22M-$0.25-5.80Alkermes$1.56B2.95$367.07M$2.0813.36 Is OPK or ALKS more profitable? Alkermes has a net margin of 23.15% compared to OPKO Health's net margin of -26.68%. Alkermes' return on equity of 24.86% beat OPKO Health's return on equity.Company Net Margins Return on Equity Return on Assets OPKO Health-26.68% -13.17% -8.28% Alkermes 23.15%24.86%17.14% Do insiders & institutionals have more ownership in OPK or ALKS? 64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 49.7% of OPKO Health shares are owned by company insiders. Comparatively, 4.4% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, OPK or ALKS? OPKO Health has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Does the media refer more to OPK or ALKS? In the previous week, Alkermes had 6 more articles in the media than OPKO Health. MarketBeat recorded 8 mentions for Alkermes and 2 mentions for OPKO Health. Alkermes' average media sentiment score of 1.06 beat OPKO Health's score of 0.38 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alkermes 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer OPK or ALKS? OPKO Health currently has a consensus price target of $2.63, suggesting a potential upside of 81.03%. Alkermes has a consensus price target of $41.85, suggesting a potential upside of 50.58%. Given OPKO Health's higher probable upside, equities research analysts plainly believe OPKO Health is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OPKO Health 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 2.92 SummaryAlkermes beats OPKO Health on 14 of the 17 factors compared between the two stocks. Get OPKO Health News Delivered to You Automatically Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPK vs. The Competition Export to ExcelMetricOPKO HealthMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.20B$6.82B$5.79B$10.40BDividend YieldN/A1.20%5.63%4.60%P/E Ratio-5.8026.7876.4826.75Price / Sales1.61197.91531.72124.23Price / Cash21.9522.0337.9261.55Price / Book0.734.9813.726.40Net Income-$53.22M$178.07M$3.29B$271.62M7 Day Performance3.57%5.36%2.65%3.46%1 Month Performance4.32%10.93%6.01%9.87%1 Year Performance-2.03%17.52%80.02%28.45% OPKO Health Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPKOPKO Health4.3492 of 5 stars$1.45-4.0%$2.63+81.0%-8.8%$1.20B$713.10M-5.802,997High Trading VolumeALKSAlkermes4.5829 of 5 stars$26.52-1.7%$41.85+57.8%-2.0%$4.38B$1.51B12.751,800Positive NewsLGNDLigand Pharmaceuticals4.2311 of 5 stars$165.51-0.1%$176.50+6.6%+58.6%$3.24B$187.58M-41.3880Positive NewsHigh Trading VolumeFOLDAmicus Therapeutics4.0564 of 5 stars$7.73-3.3%$16.00+107.0%-24.3%$2.38B$571.16M-64.41480Analyst UpgradeMNKDMannKind4.2889 of 5 stars$5.38-3.4%$11.17+107.6%-19.0%$1.65B$301.74M48.91400Positive NewsAnalyst ForecastInsider TradeShort Interest ↓High Trading VolumeCLDXCelldex Therapeutics2.168 of 5 stars$24.50+0.2%$46.67+90.5%-40.2%$1.63B$7.02M-8.14150Analyst ForecastBCRXBioCryst Pharmaceuticals4.276 of 5 stars$7.70-2.7%$16.70+116.9%-5.5%$1.62B$557.51M-42.78530Positive NewsNVAXNovavax4.2081 of 5 stars$8.08+1.3%$14.29+76.8%-30.4%$1.31B$1.08B3.541,990INVAInnoviva4.8401 of 5 stars$19.55+0.9%$42.75+118.7%-2.4%$1.23B$358.71M63.07100Positive NewsShort Interest ↓DVAXDynavax Technologies4.3136 of 5 stars$9.36-0.5%$24.33+160.0%-15.7%$1.10B$316.27M-20.35350ZBIOZenas BioPharma1.095 of 5 stars$21.95+8.5%$36.67+67.0%N/A$924.31M$5M-6.18N/A Related Companies and Tools Related Companies ALKS Competitors LGND Competitors FOLD Competitors MNKD Competitors CLDX Competitors BCRX Competitors NVAX Competitors INVA Competitors DVAX Competitors ZBIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPK) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OPKO Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OPKO Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OPK Stock Alerts